Massively Parallel Sequencing for Monitoring Genetic Consistency and Quality Control of Live Viral Vaccines

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 2010 Nov 3

PMID 21041640

Citations 36

Authors

Alexander Neverov

Konstantin Chumakov

Affiliations

Soon will be listed here.

Abstract

Intrinsic genetic instability of RNA viruses may lead to the accumulation of revertants during manufacture of live viral vaccines, requiring rigorous quality control to ensure vaccine safety. Each lot of oral poliovirus vaccine (OPV) is tested for neurovirulence in animals and also for the presence of neurovirulent revertants. Mutant analysis by PCR and restriction enzyme cleavage (MAPREC) is used to measure the frequency of neurovirulent mutations at the 5' untranslated region (UTR) of the viral genome that correlate with the level of neurovirulence determined by the monkey neurovirulence test. However, MAPREC can only monitor mutations at a few genomic loci and miss mutations at other sites that could adversely affect vaccine quality. Here we propose to use massively parallel sequencing (MPS) for sensitive detection and quantification of all mutations in the entire genome of attenuated viruses. Analysis of vaccine samples and reference preparations demonstrated a perfect agreement with MAPREC results. Quantitative MPS analysis of validated reference preparations tested by MAPREC produced identical results, suggesting that the method could take advantage of the existing reference materials and be used as a replacement for the MAPREC procedure in lot release of OPV. Patterns of mutations present at a low level in vaccine preparations were characteristic of seed viruses used for their manufacture and could be used for identification of individual batches. This approach may represent the ultimate tool for monitoring genetic consistency of live viral vaccines.

Citing Articles

Long-Read High-Throughput Sequencing (HTS) Revealed That the Sf-Rhabdovirus X Genome Contains a 3.7 kb Internal Duplication.

Ma H, Bosma T, Khan A Viruses. 2023; 15(10).

PMID: 37896775 PMC: 10612052. DOI: 10.3390/v15101998.

Rapid emergence and transmission of virulence-associated mutations in the oral poliovirus vaccine following vaccination campaigns.

Walter K, Altamirano J, Huang C, Carrington Y, Zhou F, Andrews J NPJ Vaccines. 2023; 8(1):137.

PMID: 37749086 PMC: 10520055. DOI: 10.1038/s41541-023-00740-9.

A Development of Rapid Whole-Genome Sequencing of Using a Portable One-Step Amplicon-Based High Accuracy Nanopore System.

Park K, Noh J, Kim K, Kim J, Cho H, Kim S Viruses. 2023; 15(7).

PMID: 37515228 PMC: 10386077. DOI: 10.3390/v15071542.

Genetic stabilization of attenuated oral vaccines against poliovirus types 1 and 3.

Yeh M, Smith M, Carlyle S, Konopka-Anstadt J, Burns C, Konz J Nature. 2023; 619(7968):135-142.

PMID: 37316671 PMC: 10322712. DOI: 10.1038/s41586-023-06212-3.

Rapid emergence and transmission of virulence-associated mutations in the oral poliovirus vaccine following vaccination campaigns.

Walter K, Altamirano J, Huang C, Carrington Y, Zhou F, Andrews J medRxiv. 2023; .

PMID: 36993386 PMC: 10055580. DOI: 10.1101/2023.03.16.23287381.

References

Victoria J, Wang C, Jones M, Jaing C, McLoughlin K, Gardner S . Viral nucleic acids in live-attenuated vaccines: detection of minority variants and an adventitious virus. J Virol. 2010; 84(12):6033-40. PMC: 2876658. DOI: 10.1128/JVI.02690-09. View

Tatem J, DiMichele S, Waterfield W, Georgiu A, Mento S . Identification and characterization of a new base substitution in the vaccine strain of Sabin 3 poliovirus. Virology. 1991; 185(2):934-7. DOI: 10.1016/0042-6822(91)90576-w. View

Eckerle L, Becker M, Halpin R, Li K, Venter E, Lu X . Infidelity of SARS-CoV Nsp14-exonuclease mutant virus replication is revealed by complete genome sequencing. PLoS Pathog. 2010; 6(5):e1000896. PMC: 2865531. DOI: 10.1371/journal.ppat.1000896. View

Levenbook I, Dragunsky E, Pervikovc Y . Development of a transgenic mouse neurovirulence test for oral poliovirus vaccine: international collaborative study 1993-1999. Vaccine. 2000; 19(2-3):163-6. DOI: 10.1016/s0264-410x(00)00190-0. View

Mardis E . Next-generation DNA sequencing methods. Annu Rev Genomics Hum Genet. 2008; 9:387-402. DOI: 10.1146/annurev.genom.9.081307.164359. View

Rozera G, Abbate I, Bruselles A, Vlassi C, DOffizi G, Narciso P . Massively parallel pyrosequencing highlights minority variants in the HIV-1 env quasispecies deriving from lymphomonocyte sub-populations. Retrovirology. 2009; 6:15. PMC: 2660291. DOI: 10.1186/1742-4690-6-15. View

Rogers Y, Venter J . Genomics: massively parallel sequencing. Nature. 2005; 437(7057):326-7. DOI: 10.1038/437326a. View

Novella I, Domingo E, Holland J . Rapid viral quasispecies evolution: implications for vaccine and drug strategies. Mol Med Today. 1995; 1(5):248-53. PMC: 7128888. DOI: 10.1016/s1357-4310(95)91551-6. View

Sabin A . Present position of immunization against poliomyelitis with live virus vaccines. Br Med J. 1959; 1(5123):663-80. PMC: 1993129. DOI: 10.1136/bmj.1.5123.663. View

10.

Taffs R, Chumakov K, Rezapkin G, Lu Z, Douthitt M, Dragunsky E . Genetic stability and mutant selection in Sabin 2 strain of oral poliovirus vaccine grown under different cell culture conditions. Virology. 1995; 209(2):366-73. DOI: 10.1006/viro.1995.1268. View

11.

Cherkasova E, Laassri M, Chizhikov V, Korotkova E, Dragunsky E, Agol V . Microarray analysis of evolution of RNA viruses: evidence of circulation of virulent highly divergent vaccine-derived polioviruses. Proc Natl Acad Sci U S A. 2003; 100(16):9398-403. PMC: 170930. DOI: 10.1073/pnas.1633511100. View

12.

Chumakov K, POWERS L, Noonan K, Roninson I, Levenbook I . Correlation between amount of virus with altered nucleotide sequence and the monkey test for acceptability of oral poliovirus vaccine. Proc Natl Acad Sci U S A. 1991; 88(1):199-203. PMC: 50777. DOI: 10.1073/pnas.88.1.199. View

13.

Orita M, Iwahana H, Kanazawa H, Hayashi K, Sekiya T . Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms. Proc Natl Acad Sci U S A. 1989; 86(8):2766-70. PMC: 286999. DOI: 10.1073/pnas.86.8.2766. View

14.

Rezapkin G, Chumakov K, Lu Z, Ran Y, Dragunsky E, Levenbook I . Microevolution of Sabin 1 strain in vitro and genetic stability of oral poliovirus vaccine. Virology. 1994; 202(1):370-8. DOI: 10.1006/viro.1994.1353. View

15.

Cann A, Stanway G, Hughes P, Minor P, Evans D, Schild G . Reversion to neurovirulence of the live-attenuated Sabin type 3 oral poliovirus vaccine. Nucleic Acids Res. 1984; 12(20):7787-92. PMC: 320200. DOI: 10.1093/nar/12.20.7787. View

16.

Chumakov K, Dragunsky E, Norwood L, Douthitt M, Ran Y, Taffs R . Consistent selection of mutations in the 5'-untranslated region of oral poliovirus vaccine upon passaging in vitro. J Med Virol. 1994; 42(1):79-85. DOI: 10.1002/jmv.1890420115. View

17.

Tsibris A, Korber B, Arnaout R, Russ C, Lo C, Leitner T . Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo. PLoS One. 2009; 4(5):e5683. PMC: 2682648. DOI: 10.1371/journal.pone.0005683. View

18.

Chumakov K, Norwood L, Parker M, Dragunsky E, Ran Y, Levenbook I . RNA sequence variants in live poliovirus vaccine and their relation to neurovirulence. J Virol. 1992; 66(2):966-70. PMC: 240798. DOI: 10.1128/JVI.66.2.966-970.1992. View

19.

Proudnikov D, Kirillov E, Chumakov K, Donlon J, Rezapkin G, Mirzabekov A . Analysis of mutations in oral poliovirus vaccine by hybridization with generic oligonucleotide microchips. Biologicals. 2000; 28(2):57-66. DOI: 10.1006/biol.1999.0241. View

20.

Sabin A . Oral poliovirus vaccine: history of its development and use and current challenge to eliminate poliomyelitis from the world. J Infect Dis. 1985; 151(3):420-36. DOI: 10.1093/infdis/151.3.420. View